Dr. Megan R. Haymart received her medical degree from Johns Hopkins University School of Medicine in 2002, completed internal medicine residency at Johns Hopkins Hospital in 2005, and then completed fellowship in endocrinology, diabetes and metabolism at the University of Wisconsin in 2007. In 2009, she joined the University of Michigan faculty as Assistant Professor of Medicine.
Dr. Haymart is involved in creating the National Comprehensive Cancer Network thyroid carcinoma guidelines, is on the editorial boards of the Journal of Clinical Endocrinology and Metabolism and Thyroid, and is associate editor for VideoEndocrinology. She is active in the American Thyroid Association and the Endocrine Society and currently serves on the finance committee for the American Thyroid Association.
Dr. Haymart’s research focuses on variation in the management of thyroid cancer with an emphasis on the role of patients, providers, and health systems in thyroid cancer treatment. She also studies thyroid cancer outcomes and the rise in thyroid cancer incidence. She is Principal Investigator of the NCI-funded research grant “Treatment Decision Making in Low-Risk Thyroid Cancer.”
Banerjee M, Muenz DG, Chang JT, Papaleontiou M, Haymart MR. Tree-based model for thyroid cancer prognostication. J Clin Endocrinol Metab 2014; 99(10):3737-45
Esfandiari NH, Hughes DT, Yin H, Banerjee M, Haymart MR. The effect of extent of surgery and number of lymph node metastases on overall survival in patients with medullary thyroid cancer. J Clin Endocrinol Metab 2014; 99(2):448-54
Haymart MR, Banerjee M, Yang D, Stewart AK, Sisson JC, Koenig RJ, Doherty GM, Griggs JJ. Variation in the management of thyroid cancer. J Clin Endocrinol Metab 2013; 98(5):2001-8
Haymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ. Use of radioactive iodine for thyroid cancer. JAMA 2011; 306(7):721-8